You are viewing: US Al in Clinical Trials Market analysis
Part of: AI in Clinical Trials Market (Global)

The US Al in Clinical Trials Market was valued at $192.51 Million in 2024 and projected to reach to $407.85 Million by 2029, representing a compound annual growth rate of 13.3%. The US AI in Clinical Trials Market is poised for sustained expansion through 2029, driven by increasing pressure to reduce trial timelines and costs while improving data quality.

US Al in Clinical Trials Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Al in Clinical Trials Market Trends and Insights

  • The US market is driven by increasing adoption of artificial intelligence technologies to streamline trial design, patient recruitment, and data analysis across pharmaceutical and biotech sectors.
  • The US represents a critical hub for clinical trial innovation, with healthcare organizations leveraging AI to reduce trial timelines, improve patient outcomes, and enhance regulatory compliance. Growth in the US market is fueled by rising R&D investments, regulatory support for digital health solutions, and the need to accelerate drug development cycles.
  • The US clinical trials landscape is increasingly competitive, with sponsors and contract research organizations (CROs) integrating AI-powered platforms for real-time monitoring, predictive analytics, and protocol optimization.
  • By 2029, the US market is expected to nearly double in value, reflecting the sector's commitment to modernizing trial operations and improving efficiency across the entire clinical development pipeline..

Key Market Statistics

  • CAGR (2024-2029) 13.3% CAGR
  • Market Size, 2024 ~USD 192.51 Million
  • Forecast, 2029 ~USD 407.85 Million
  • Country US

US Al in Clinical Trials Market Overview

Market Valuation Growth :

The US AI in Clinical Trials Market is valued at $192.51 million in 2024, with a projected CAGR of 13.3%, reaching $407.85 million by 2029, demonstrating strong double-digit growth momentum.

Technology Adoption Leadership :

US pharmaceutical and biotech companies are rapidly integrating AI for trial design optimization, patient recruitment acceleration, and real-time data analysis, positioning the country as a global innovation leader.

Regulatory Support & Infrastructure :

The FDA's progressive stance on AI/ML in drug development, combined with robust healthcare IT infrastructure and high R&D spending, creates a favorable environment for AI clinical trial solutions in the US market.

Patient Recruitment Innovation :

US clinical trial operators are leveraging AI-powered patient matching and recruitment platforms to reduce enrollment timelines, improve diversity, and enhance trial efficiency across therapeutic areas.

US Al in Clinical Trials Market Dynamics

  • Major pharmaceutical companies and Contract Research Organizations (CROs) are investing heavily in AI-powered solutions for protocol design, patient stratification, and adverse event monitoring.
  • Regulatory clarity from the FDA regarding AI validation standards is accelerating adoption across the industry. Key growth catalysts include the rising complexity of clinical trials, labor shortages in trial management, and the need for real-world evidence integration.
  • US biotech firms and academic medical centers are increasingly partnering with AI vendors to enhance competitive advantage.
  • The market will likely see consolidation among AI solution providers and deeper integration with existing clinical trial management systems..

Market Ecosystem

logo-mobile

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • The US AI in Clinical Trials Market is valued at $192.51 million in 2024 and is forecast to reach $407.85 million by 2029, representing a 13.3% CAGR.
    • The US market is driven by pharmaceutical and biotech companies seeking to accelerate drug development, reduce costs, and improve patient recruitment efficiency.
    • AI adoption in the US is accelerating due to regulatory support, increased R&D spending, and the competitive pressure to modernize clinical trial operations.
    • The US market's near-doubling in value by 2029 reflects strong demand for AI-powered solutions in trial design, data management, and real-time monitoring.

    Al in Clinical Trials Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment DRUG REPURPOSING (Function)
    Forecast Period 2024-2029
    Growth Rate CAGR of 12.4% from 2024 to 2029
    Largest Segment CLOUD-BASED SOLUTIONS (Deployment Mode)
    Market Size Base Year (Billions) ~USD 1.36 (2024)
    Revenue Forecast (Billions) ~USD 2.44 (2029)
    Segments Covered Offering, Function, Type, Phase, Deployment Mode, Indication, Technology, Application, End User

    US Al in Clinical Trials Market Report Segmentation

    9 segment dimensions are covered across the global market.

    By Offering

    • End-To-End Solutions
    • Niche Solutions
    • Services
    • Technology Providers

    By Function

    • Adverse Event Prediction & Detection
    • Data Management & Quality Control
    • Drug Repurposing
    • Patient Recruitment
    • Regulatory Compliance
    • Trial Design Optimization

    By Type

    • Deep Learning
    • Hybrid Cloud-Based Solutions
    • Multi Cloud-Based Solutions
    • Other Machine Learning Technologies
    • Patient Engagement & Retention
    • Patient Identification & Screening
    • Predictive Modeling
    • Private Cloud-Based Solutions
    • Public Cloud-Based Solutions
    • Reinforcement Learning
    • Risk Management
    • Site Optimization
    • Supervised Learning
    • Unsupervised Learning
    • Workflow Management

    By Phase

    • Phase I Clinical Trials
    • Phase Ii Clinical Trials
    • Phase Iii Clinical Trials
    • Phase Iv Clinical Trials

    By Deployment Mode

    • Cloud-Based Solutions
    • On-Premises Solutions

    By Indication

    • Cardiovascular Diseases
    • Immunological Diseases
    • Immunology Diseases
    • Infectious Diseases
    • Metabolic Diseases
    • Neurological Diseases
    • Oncology
    • Other Diseases

    By Technology

    • Computer Vision
    • Machine Learning
    • Natural Language Processing
    • Other Technologies
    • Robotic Process Automation

    By Application

    • Biomarkers
    • Cell & Gene Therapy
    • Gene & Cell Therapy
    • Medical Devices & Diagnostics
    • Regenerative Medicines

    By End User

    • Contract Research Organizations
    • Healthcare Providers
    • Medical Device Manufacturers
    • Pharmaceutical & Biopharmaceutical Companies
    • Research Institutes & Laboratories

    US: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030

    Segment202220232024202520262027202820292030CAGR (%)
    CONTRACT RESEARCH ORGANIZATIONS38.1743.6349.8556.936574.1784.6196.49109.9814.1
    HEALTHCARE PROVIDERS60.7468.1976.5385.8496.26107.9120.9135.41151.6212.1
    MEDICAL DEVICE MANUFACTURERS49.7857.8867.2778.1590.76105.36122.26141.81164.4316.1
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES171.22193.94219.59248.53281.16317.96359.44406.17458.813.1
    RESEARCH INSTITUTES & LABORATORIES73.7585.0398.01112.91130.03149.69172.26198.16227.8615.1
    TOTAL393.67448.68511.24582.37663.22755.09859.47978.041112.6913.8

    Target Audience

    • Pharmaceutical & Biotech Executives : C-suite leaders and R&D heads need US market intelligence to justify AI investments, allocate budgets for clinical trial modernization, and stay competitive in drug development timelines.
    • AI & Software Solution Vendors : Companies developing clinical trial AI platforms require detailed US market sizing, growth forecasts, and adoption trends to refine product roadmaps, identify customer segments, and plan sales expansion.
    • Contract Research Organizations (CROs) : US-based CROs need market data to understand AI adoption rates among clients, benchmark service offerings, and develop AI-enhanced trial management capabilities to retain and attract sponsors.
    • Investment & Private Equity Firms : Investors evaluating healthcare IT and clinical trial tech opportunities require validated US market forecasts and growth drivers to assess portfolio companies, identify acquisition targets, and guide funding decisions.
    • Healthcare Consultants & Analysts : Strategy consultants and market researchers need authoritative US-specific data to support client recommendations, competitive analyses, and market entry strategies in the clinical trials AI space.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Quantified US market data with precise 2024 baseline ($192.51M) and 2029 forecast ($407.85M) enables accurate financial planning, investment decisions, and revenue projections specific to the American market.
    • Competitive Landscape Intelligence : Understand which US pharmaceutical, biotech, and CRO players are leading AI adoption, identify market gaps, and benchmark your solutions against competitors operating in the world's largest clinical trial market.
    • Regulatory & Reimbursement Insights : Gain clarity on FDA guidance, reimbursement pathways, and compliance requirements specific to AI in US clinical trials, reducing market entry risks and accelerating go-to-market strategies.
    • Technology Adoption Trends : Identify which AI applications (patient recruitment, trial design, data analysis) are gaining traction in US trials, helping vendors prioritize product development and marketing efforts effectively.
    • Strategic Partnership Opportunities : Discover high-potential collaboration targets among US CROs, academic medical centers, and pharma companies investing in AI, enabling strategic alliances and revenue acceleration in this high-growth segment.

    Frequently asked questions

    What is the current size of the US AI in Clinical Trials Market?

    The US AI in Clinical Trials Market was valued at $192.51 million in 2024 and is expected to grow to $407.85 million by 2029.

    What is the projected growth rate for the US market?

    The US market is projected to grow at a compound annual growth rate (CAGR) of 13.3% from 2024 to 2029.

    What are the primary drivers of AI adoption in US clinical trials?

    Key drivers include the need to accelerate drug development timelines, reduce trial costs, improve patient recruitment, enhance data accuracy, and meet regulatory requirements in the US healthcare system.

    Which sectors are leading AI adoption in US clinical trials?

    Pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are the primary adopters of AI technologies in the US clinical trials market.

    How much will the US market grow in absolute value by 2029?

    The US market is expected to grow by $215.34 million, more than doubling from $192.51 million in 2024 to $407.85 million by 2029.

    RESEARCH METHODOLOGY

    The study involved significant activities to estimate the current size of the AI in clinical trials market. Exhaustive secondary research was done to collect information on the AI in clinical trials market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in clinical trials market.

    Secondary Research

    This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in clinical trials solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

    Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in clinical trials vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

    Primary Research

    In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in clinical trials market.

    After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in clinical trials solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

    In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

    Breakdown of Primary Participants:

    AI in Clinical Trials Market

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in clinical trials market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research.
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
    AI in Clinical Trials Market

    Data Triangulation

    After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    The AI in clinical trials market refers to the utilization of artificial intelligence-based tools to improve the different phases as well as steps of clinical research process activity such as trial development, enrolment of patients, data management and analysis and therapeutic monitoring. Al assists in accomplishing such tasks by automating the collection of data, enhancing the efficiency of patient matching and improving prediction of outcomes of trials which in turn helps in reducing the timeline and cost associated with these processes. This allows for a clearer understanding of large amounts of information, for example, within patient charts or genome information, so that the appropriate information is available for making decisions for particular trials. Clinical trials become highly efficient, cheaper, and more precise with the integration of Al technologies into the processes which significantly helps in drug development reducing the waiting time and the success rate improves. With more and more applications of AI in the healthcare sector, this healthcare services market is projected to grow as there will be a rise in the need for improved clinical research within a short turnaround time.

    Stakeholders

    • Pharmaceutical and Biotechnology Companies
    • Contract Research Organizations (CROs)
    • Technology and AI Companies
    • Regulatory Authorities
    • Hospitals and Healthcare Providers
    • Patients and Patient Advocacy Groups
    • Clinical Trial Investigators and Site Coordinators
    • Data Management and Analytics Firms
    • Academic Institutions and Research Organizations
    • Investors and Venture Capital Firms
    • Clinical Trial Software Providers
    • Ethics Committees and Institutional Review Boards (IRBs)
    • Insurance Companies

    Report Objectives

    • To define, describe, and forecast the AI in clinical trials market based on offering, function, phase, deployment mode, indication, technology, application, end user, and region.
    • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
    • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
    • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
    • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
    • To profile the key players and comprehensively analyze their market sizes and core competencies.
    • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally.

     

    Get the Full AI in Clinical Trials Market Report

    Full forecast, segment splits, and company analysis for all AI in Clinical Trials Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status